Emergent BioSolutions Inc/ US29089Q1058 /
6/29/2022 9:59:55 PM | Chg. -0.70 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
30.56USD | -2.24% | 30,707 Turnover: 944,327.44 |
-Bid Size: - | -Ask Size: - | 1.53 bill.USD | 0.00% | 5.27 |
Assets
|
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 376.4000 | 407.2000 | 510.2000 | 542.3000 | 644.1000 | ||||||
Intangible Assets | 33.9000 | 119.6000 | 761.6000 | 712.9000 | 663.1000 | ||||||
Long-Term Investments | - | - | - | - | - | ||||||
Fixed Assets | - | - | - | - | - | ||||||
Inventories | 74 | 142.8000 | 205.8000 | 222.5000 | 307 | ||||||
Accounts Receivable | 138.5000 | 143.7000 | 262.5000 | 270.7000 | 230.9000 | ||||||
Cash and Cash Equivalents | 271.5000 | 178.3000 | 112.2000 | 167.8000 | 621.3000 | ||||||
Current Assets | 510.2000 | 485.4000 | 620.8000 | 686.2000 | 1,195.9000 | ||||||
Total Assets | 970.1000 | 1,070.2000 | 2,229.4000 | 2,327.3000 | 2,883.2000 |
Liabilities
|
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | 34.6000 | 41.8000 | 80.7000 | 94.8000 | 136.1000 | ||||||
Long-term debt | - | - | - | - | - | ||||||
Liabilities to Banks | - | - | - | - | - | ||||||
Provisions | - | - | 72 | 63.9000 | 53.2000 | ||||||
Liabilities | 373.9000 | 157.9000 | 1,218.5000 | 1,238.8000 | 1,436.2000 | ||||||
Share Capital | .0410 | .0500 | .1000 | .1000 | .1000 | ||||||
Total Equity | 596.2000 | 912.3000 | 1,010.9000 | 1,088.5000 | 1,447 | ||||||
Minority Interests | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
Total liabilities equity | 970.1000 | 1,070.2000 | 2,229.4000 | 2,327.3000 | 2,883.2000 |
Income Statement
|
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 488.8000 | 560.9000 | 782.4000 | 1,106 | 1,555.4000 | ||||||
Depreciation (total) | - | - | - | - | - | ||||||
Operating Result | 105.5000 | 124.3000 | 89.8000 | 114.1000 | 433.8000 | ||||||
Interest Income | -6.5000 | -4.8000 | -9.9000 | -38.4000 | -31.3000 | ||||||
Income Before Taxes | 99.2000 | 118.6000 | 81.5000 | 77.4000 | 407.2000 | ||||||
Income Taxes | 36.7000 | 36 | 18.8000 | 22.9000 | 102.1000 | ||||||
Minority Interests Profit | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
Net Income | 51.8000 | 82.6000 | 62.7000 | 54.5000 | 305.1000 |
Per Share
Cash Flow
|
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | 53.5000 | 208.1000 | 41.8000 | 188 | 536 | ||||||
Cash Flow from Investing Activities | -76.3000 | -249.9000 | -897.2000 | -96.9000 | -151 | ||||||
Cash Flow from Financing | -18.6000 | -51.4000 | 788.7000 | -35.9000 | 69.5000 | ||||||
Decrease / Increase in Cash | -41.3000 | -93.2000 | -66.9000 | 55.6000 | 453.5000 | ||||||
Employees | 1,098 | 1,256 | 1,705 | 1,834 | 2,200 |